July 2, 2020
Mountain View, CA – July 2, 2020 Specific Diagnostics has appointed FLG Partner Greg Curhan to the company’s Advisory Board. He brings both financial and capital markets expertise to Specific as it launches the Reveal rapid susceptibility testing system in Europe in the 2nd half of 2020. Mr. Curhan joined Specific’s Advisory Board effective July 1, 2020, with an initial 3-year term.
“Greg is joining us at a time when we are scaling up, and his acumen in financial systems as well as the capital markets is a timely addition to the perspective of our lead investor Telegraph Hill Partners,” said Dr. Paul A. Rhodes, Specific’s founder and CEO. “I look forward to working closely
with him to ensure that we build a company that both brings innovative technology to an important medical need while building value for its shareholders.”
“I am delighted to have the chance to participate in advising Specific at this exciting stage in its development,” said Mr. Curhan. “The company reminds me of some of the most successful that we had the good fortune to finance at our bank: a great technology, with a product relevant to
market needs present today, and management and Board focused on execution. I look forward to working with Paul and the Board to help them do what it takes to capitalize on this sort of opportunity. It is clear to me that the global appetite for infectious disease diagnostics is burgeoning, for good reason, and the Company will have a great many choices to navigate. It will be exciting for me to provide them advice from my experience both as an investment banker and CFO of both public and private companies.”
Read the full press release here.